|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 1988 |
FusionGeneSummary for ANXA2_SPRR2A |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: ANXA2_SPRR2A | Fusion gene ID: 1988 | Hgene | Tgene | Gene symbol | ANXA2 | SPRR2A | Gene ID | 302 | 6700 |
| Gene name | annexin A2 | small proline rich protein 2A | |
| Synonyms | ANX2|ANX2L4|CAL1H|HEL-S-270|LIP2|LPC2|LPC2D|P36|PAP-IV | - | |
| Cytomap | 15q22.2 | 1q21.3 | |
| Type of gene | protein-coding | protein-coding | |
| Description | annexin A2annexin IIannexin-2calpactin I heavy chaincalpactin I heavy polypeptidecalpactin-1 heavy chainchromobindin 8epididymis secretory protein Li 270lipocortin IIplacental anticoagulant protein IVprotein I | small proline-rich protein 2A2-1SPR-2A | |
| Modification date | 20180522 | 20180523 | |
| UniProtAcc | P07355 | P35326 | |
| Ensembl transtripts involved in fusion gene | ENST00000396024, ENST00000451270, ENST00000332680, ENST00000421017, ENST00000557937, | ENST00000392653, | |
| Fusion gene scores | * DoF score | 7 X 7 X 3=147 | 3 X 3 X 2=18 |
| # samples | 8 | 3 | |
| ** MAII score | log2(8/147*10)=-0.877744249949002 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: ANXA2 [Title/Abstract] AND SPRR2A [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | ANXA2 | GO:0001921 | positive regulation of receptor recycling | 22848640 |
| Hgene | ANXA2 | GO:0031340 | positive regulation of vesicle fusion | 2138016 |
| Hgene | ANXA2 | GO:0032804 | negative regulation of low-density lipoprotein particle receptor catabolic process | 22848640 |
| Hgene | ANXA2 | GO:0036035 | osteoclast development | 7961821 |
| Hgene | ANXA2 | GO:0051290 | protein heterotetramerization | 23091277|23861394 |
| Hgene | ANXA2 | GO:1905581 | positive regulation of low-density lipoprotein particle clearance | 22848640 |
| Hgene | ANXA2 | GO:1905597 | positive regulation of low-density lipoprotein particle receptor binding | 22848640 |
| Hgene | ANXA2 | GO:1905602 | positive regulation of receptor-mediated endocytosis involved in cholesterol transport | 22848640 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | BE181532 | ANXA2 | chr15 | 60657832 | + | SPRR2A | chr1 | 153028861 | + |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-3UTR | ENST00000396024 | ENST00000392653 | ANXA2 | chr15 | 60657832 | + | SPRR2A | chr1 | 153028861 | + |
| intron-3UTR | ENST00000451270 | ENST00000392653 | ANXA2 | chr15 | 60657832 | + | SPRR2A | chr1 | 153028861 | + |
| intron-3UTR | ENST00000332680 | ENST00000392653 | ANXA2 | chr15 | 60657832 | + | SPRR2A | chr1 | 153028861 | + |
| intron-3UTR | ENST00000421017 | ENST00000392653 | ANXA2 | chr15 | 60657832 | + | SPRR2A | chr1 | 153028861 | + |
| intron-3UTR | ENST00000557937 | ENST00000392653 | ANXA2 | chr15 | 60657832 | + | SPRR2A | chr1 | 153028861 | + |
Top |
FusionProtFeatures for ANXA2_SPRR2A |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| ANXA2 | SPRR2A |
| Calcium-regulated membrane-binding protein whoseaffinity for calcium is greatly enhanced by anionic phospholipids.It binds two calcium ions with high affinity. May be involved inheat-stress response. Inhibits PCSK9-enhanced LDLR degradation,probably reduces PCSK9 protein levels via a translationalmechanism but also competes with LDLR for binding with PCSK9(PubMed:18799458, PubMed:24808179, PubMed:22848640).{ECO:0000269|PubMed:18799458, ECO:0000269|PubMed:22848640,ECO:0000269|PubMed:24808179}. | Cross-linked envelope protein of keratinocytes. It is akeratinocyte protein that first appears in the cell cytosol, butultimately becomes cross-linked to membrane proteins bytransglutaminase. All that results in the formation of aninsoluble envelope beneath the plasma membrane. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ANXA2_SPRR2A |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ANXA2_SPRR2A |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ANXA2_SPRR2A |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | ANXA2 | P07355 | DB00031 | Tenecteplase | Annexin A2 | biotech | approved |
| Hgene | ANXA2 | P07355 | DB11638 | Artenimol | Annexin A2 | small molecule | approved|investigational |
Top |
RelatedDiseases for ANXA2_SPRR2A |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | ANXA2 | C0007137 | Squamous cell carcinoma | 1 | CTD_human |
| Hgene | ANXA2 | C0023467 | Leukemia, Myelocytic, Acute | 1 | CTD_human |
| Hgene | ANXA2 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Hgene | ANXA2 | C0023903 | Liver neoplasms | 1 | CTD_human |
| Hgene | ANXA2 | C0024121 | Lung Neoplasms | 1 | CTD_human |
| Hgene | ANXA2 | C0024667 | Animal Mammary Neoplasms | 1 | CTD_human |
| Hgene | ANXA2 | C0026640 | Mouth Neoplasms | 1 | CTD_human |
| Hgene | ANXA2 | C0027626 | Neoplasm Invasiveness | 1 | CTD_human |
| Hgene | ANXA2 | C0029456 | Osteoporosis | 1 | CTD_human |
| Hgene | ANXA2 | C0043094 | Weight Gain | 1 | CTD_human |
| Hgene | ANXA2 | C0345967 | Malignant mesothelioma | 1 | CTD_human |
| Hgene | ANXA2 | C4277682 | Chemical and Drug Induced Liver Injury | 1 | CTD_human |
| Tgene | SPRR2A | C0038356 | Stomach Neoplasms | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|